ProPhase Labs Total Liabilities 2010-2025 | PRPH

ProPhase Labs total liabilities from 2010 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

ProPhase Labs Total Liabilities 2010-2025 | PRPH

ProPhase Labs total liabilities from 2010 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$69.6B
Zoetis (ZTS)$69B
Takeda Pharmaceutical (TAK)$48.7B
Daiichi Sankyo, - (DSNKY)$47.9B
BeOne Medicines - (ONC)$34.4B
Sandoz Group AG (SDZNY)$26.7B
Summit Therapeutics (SMMT)$19.3B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14.9B
United Therapeutics (UTHR)$14B
Neurocrine Biosciences (NBIX)$13.4B
IPSEN (IPSEY)$11.3B
Orion OYJ (ORINY)$11.2B
Eisai (ESAIY)$9.1B
Madrigal Pharmaceuticals (MDGL)$9B
Corcept Therapeutics (CORT)$7.5B
Grifols, S.A (GRFS)$6.9B
Stevanato Group S.p.A (STVN)$6.9B
Ionis Pharmaceuticals (IONS)$6.9B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.7B
Procaps Group, S.A (PROCF)$3.2B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.8B
NewAmsterdam Pharma (NAMS)$2.8B
Hypermarcas (HYPMY)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.1B